+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

In patients with metastatic melanoma treated with patient-specific vaccines derived from short-term autologous tumor cell lines, is an immune response to tumor stem cells responsible for long-term survival?



In patients with metastatic melanoma treated with patient-specific vaccines derived from short-term autologous tumor cell lines, is an immune response to tumor stem cells responsible for long-term survival?








(PDF emailed within 1 workday: $29.90)

Accession: 021178179

Download citation: RISBibTeXText


Related references

Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Critical Reviews in Oncology/Hematology 39(1-2): 115-123, 2001

Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer BioTherapy and Radiopharmaceuticals 22(3): 309-321, 2007

Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer BioTherapy and Radiopharmaceuticals 17(1): 51-66, 2002

Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer BioTherapy and Radiopharmaceuticals 30(5): 187-194, 2016

Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. Journal of Immunology 158(8): 3787-3795, 1997

Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Review of Vaccines 13(1): 117-130, 2014

Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer BioTherapy and Radiopharmaceuticals 16(1): 47-54, 2001

Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer. Cancer BioTherapy & Radiopharmaceuticals 15(2): 161-168, 2000

Gefitinib-induced cell death in short term fresh tumor cultures predicts for long term patient survival in previously-treated non-small cell lung cancer. Journal of Clinical Oncology 24(18_suppl): 17117-17117, 2016

Cytotoxicity in vitro of blood lymphocytes from bladder cancer patients and controls to allogeneic or autologous tumor cells derived from established cell lines or short-term cultures. International Journal of Cancer 25(1): 33-43, 1980

Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer BioTherapy and Radiopharmaceuticals 24(3): 311-319, 2009

IL-10 and IL-2 levels in melanoma patients undergoing immunotherapy with vaccines derived from autologous tumor cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 42: 684, 2001

Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer BioTherapy and Radiopharmaceuticals 13(3): 165-176, 2000

Detection and long-term in vivo monitoring of individual tumor-specific T cell clones in patients with metastatic melanoma. Journal of Immunology 178(11): 6789-6795, 2007

Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney. Pediatric Blood and Cancer 52(7): 888-890, 2009